Shien Guo

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

Thierry Façon, Meletios Α. Dimopoulos, Nathalie Meuleman et al. · Leukemia · 2019 · 230 citations · Full text

Medicine, Geriatric Medicine, Oncology +17

Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma

Michel Delforge, Nina Shah, Jesús F. San Miguel et al. · Blood Advances · 2021 · 63 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening

Glenn Phillips, Kathleen W. Wyrwich, Shien Guo et al. · Multiple Sclerosis Journal · 2014 · 60 citations · Full text

Social Sciences, Neurology, Psychology +14

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States

C. Pelligra, Kejal Parikh, Shien Guo et al. · Clinical Therapeutics · 2017 · 46 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

COST-EFFECTIVENESS OF ADJUNCTIVE HYPERBARIC OXYGEN IN THE TREATMENT OF DIABETIC ULCERS

Shien Guo, Michael A. Counte, Kathleen N. Gillespie et al. · International Journal of Technology Assessment in Health Care · 2003 · 44 citations

Pharmacy, Pharmacoeconomics, Cost-effectiveness Analysis +16